D'Andrea, David
Overview
| Works: | 15 works in 15 publications in 3 languages and 24 library holdings |
|---|---|
| Genres: | Academic theses |
| Roles: | Author, Other |
Publication Timeline
.
Most widely held works by
David D'Andrea
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer by
Shōji Kimura(
)
1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide
1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide
Neoadjuvant therapy in urothelial cancer New therapies on the horizon by Stephan Brönimann(
)
1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide
1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide
Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization by
David D'Andrea(
)
1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide
1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer by
Francesco Soria(
)
1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide
1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer by
Francesco Soria(
)
1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide
1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant
prostate cancer by Bernhard Grubmüller(
)
1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide
1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide
Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial
Bladder Cancer by
Andrea Mari(
)
1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide
1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide
Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder by Mohammad Abufaraj(
)
1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide
1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide
Langzeiterfahrung beim Einsatz von Botulinumtoxin-A zur Behandlung neurogener und nicht neurogener Blasenfunktionsstörungen by
David D'Andrea(
Book
)
1 edition published in 2014 in German and held by 2 WorldCat member libraries worldwide
1 edition published in 2014 in German and held by 2 WorldCat member libraries worldwide
Biomarkers for immunotherapy in urological cancers(
)
1 edition published in 2018 in English and held by 1 WorldCat member library worldwide
Abstract : Purpose of review: Immunotherapies for urological malignancies have made tremendous progress by targeting immune checkpoints and have been implemented in clinical practice nowadays. Though siginifcant number of patients does not respond to immunotherapy. Biomarkers could help to predict response to treatment, but are still under investigation. We reviewed the literature to identify relevant biomarkers in patient treated with immunotherapy. Recent findings: A comprehensive search of PubMed through has been performed to identify important relevant publications from 2016 to 2017 on biomarkers for immunotherapies in urological cancers including reported clinical trials. In addition, abstracts of relevant oncological scientific meetings from 2017 have been implemented. Summary: Checkpoint inhibitors have shown substantial improvement in the treatment of metastatic RCC and metastatic and locally advanced urothelial cancer. There is an unmet need for the development of predictive biomarkers in order to identify patients who are more likely to respond to therapy
1 edition published in 2018 in English and held by 1 WorldCat member library worldwide
Abstract : Purpose of review: Immunotherapies for urological malignancies have made tremendous progress by targeting immune checkpoints and have been implemented in clinical practice nowadays. Though siginifcant number of patients does not respond to immunotherapy. Biomarkers could help to predict response to treatment, but are still under investigation. We reviewed the literature to identify relevant biomarkers in patient treated with immunotherapy. Recent findings: A comprehensive search of PubMed through has been performed to identify important relevant publications from 2016 to 2017 on biomarkers for immunotherapies in urological cancers including reported clinical trials. In addition, abstracts of relevant oncological scientific meetings from 2017 have been implemented. Summary: Checkpoint inhibitors have shown substantial improvement in the treatment of metastatic RCC and metastatic and locally advanced urothelial cancer. There is an unmet need for the development of predictive biomarkers in order to identify patients who are more likely to respond to therapy
Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guerin immunotherapy for T1G3/HG
bladder cancer by
David D'Andrea(
)
1 edition published in 2021 in English and held by 1 WorldCat member library worldwide
Purpose: To investigate the association of patients' sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette-Guerin (BCG) for T1G3/HG urinary bladder cancer (UBC). Materials and methods: We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing data using multiple imputations and adjusted for covariate imbalance between males and females using inverse probability weighting (IPW). Crude and IPW-adjusted Cox regression analyses were used to estimate the hazard ratios (HR) with their 95% confidence intervals (CI) for the association of patients' sex with HG-recurrence and disease progression. Results: A total of 2170 (82%) males and 465 (18%) females were available for analysis. Overall, 1090 (50%) males and 244 (52%) females experienced recurrence, and 391 (18%) males and 104 (22%) females experienced disease progression. On IPW-adjusted Cox regression analyses, female sex was associated with disease progression (HR 1.25, 95%CI 1.01-1.56, p = 0.04) but not with recurrence (HR 1.06, 95%CI 0.92-1.22, p = 0.41). A total of 1056 patients were treated with adequate BCG. In these patients, on IPW-adjusted Cox regression analyses, patients' sex was not associated with recurrence (HR 0.99, 95%CI 0.80-1.24, p = 0.96), HG-recurrence (HR 1.00, 95%CI 0.78-1.29, p = 0.99) or disease progression (HR 1.12, 95%CI 0.78-1.60, p = 0.55). Conclusion: Our analysis generates the hypothesis of a differential response to BCG between males and females if not adequately treated. Further studies should focus on sex-based differences in innate and adaptive immune system and their association with BCG response
1 edition published in 2021 in English and held by 1 WorldCat member library worldwide
Purpose: To investigate the association of patients' sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette-Guerin (BCG) for T1G3/HG urinary bladder cancer (UBC). Materials and methods: We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing data using multiple imputations and adjusted for covariate imbalance between males and females using inverse probability weighting (IPW). Crude and IPW-adjusted Cox regression analyses were used to estimate the hazard ratios (HR) with their 95% confidence intervals (CI) for the association of patients' sex with HG-recurrence and disease progression. Results: A total of 2170 (82%) males and 465 (18%) females were available for analysis. Overall, 1090 (50%) males and 244 (52%) females experienced recurrence, and 391 (18%) males and 104 (22%) females experienced disease progression. On IPW-adjusted Cox regression analyses, female sex was associated with disease progression (HR 1.25, 95%CI 1.01-1.56, p = 0.04) but not with recurrence (HR 1.06, 95%CI 0.92-1.22, p = 0.41). A total of 1056 patients were treated with adequate BCG. In these patients, on IPW-adjusted Cox regression analyses, patients' sex was not associated with recurrence (HR 0.99, 95%CI 0.80-1.24, p = 0.96), HG-recurrence (HR 1.00, 95%CI 0.78-1.29, p = 0.99) or disease progression (HR 1.12, 95%CI 0.78-1.60, p = 0.55). Conclusion: Our analysis generates the hypothesis of a differential response to BCG between males and females if not adequately treated. Further studies should focus on sex-based differences in innate and adaptive immune system and their association with BCG response
Closing the Loop : Restoring the Hydrologic Cycle Through Architecture by
David D'Andrea(
)
1 edition published in 2016 in English and held by 1 WorldCat member library worldwide
1 edition published in 2016 in English and held by 1 WorldCat member library worldwide
Profilo istituzionale : dal medioevo all'età moderna ; La Scuola e l'Ospedale di Santa Maria dei Battuti di Treviso in età
medievale by
Giampaolo Cagnin(
Book
)
1 edition published in 2010 in Italian and held by 1 WorldCat member library worldwide
1 edition published in 2010 in Italian and held by 1 WorldCat member library worldwide
[Rezension von: Itinerario per la terraferma veneziana by
David D'Andrea(
)
1 edition published in 2016 in English and held by 1 WorldCat member library worldwide
1 edition published in 2016 in English and held by 1 WorldCat member library worldwide
Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer(
)
1 edition published in 2018 in English and held by 1 WorldCat member library worldwide
ABSTRACT: Introduction : Bladder cancer (BCa) is the fifth most frequently diagnosed cancer worldwide and is, in fact, the most expensive cancer on a per-patient to treat basis. There is a critical need to implement new tests into clinical practice to improve the quality of clinical care, decrease unnecessary invasive therapies and ultimately save costs. Currently, no molecular or genetic biomarker has been widely integrated into daily clinical practice. However, major milestones have been achieved in our understanding of the molecular alterations in BCa that will provide the basis for integrating molecular and genetic biomarkers into clinical decision making to guide management. Clinical implementation of such novel molecular and genetic concepts is the cornerstone in an effort to usher the age of precision medicine into patient care. Areas covered : In this review, the authors discuss the emerging role of molecular biomarkers in patients receiving BCG immunotherapy as well as neoadjuvant and adjuvant chemotherapy in BCa. Expert commentary : Molecular predictive and prognostic biomarkers in BCa are promising diagnostic options that will pave the way for molecular-based personalized medicine
1 edition published in 2018 in English and held by 1 WorldCat member library worldwide
ABSTRACT: Introduction : Bladder cancer (BCa) is the fifth most frequently diagnosed cancer worldwide and is, in fact, the most expensive cancer on a per-patient to treat basis. There is a critical need to implement new tests into clinical practice to improve the quality of clinical care, decrease unnecessary invasive therapies and ultimately save costs. Currently, no molecular or genetic biomarker has been widely integrated into daily clinical practice. However, major milestones have been achieved in our understanding of the molecular alterations in BCa that will provide the basis for integrating molecular and genetic biomarkers into clinical decision making to guide management. Clinical implementation of such novel molecular and genetic concepts is the cornerstone in an effort to usher the age of precision medicine into patient care. Areas covered : In this review, the authors discuss the emerging role of molecular biomarkers in patients receiving BCG immunotherapy as well as neoadjuvant and adjuvant chemotherapy in BCa. Expert commentary : Molecular predictive and prognostic biomarkers in BCa are promising diagnostic options that will pave the way for molecular-based personalized medicine
more
fewer
Audience Level
| 0 |
 |
1 | ||
| General | Special | |||
Related Identities
- Shariat, Shahrokh F. Other
- SpringerLink (Online service) Other
- Abufaraj, Mohammad Author
- Gust, Kilian M. Other
- Soria, Francesco Author
- Resch, Irene Other
- Gontero, Paolo Other
- Kimura, Shoji Author
- Moschini, Marco Other
- Karakiewicz, Pierre I. Other